Caplin Point Laboratories Limited has informed the Exchange regarding the designation as SMP
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories has designated Dr. Vinayak Dinkar Kadam as a Senior Management Personnel (SMP) of the company, effective June 27, 2025. He has been appointed as Associate Vice President – FR&D at Ticel Biopark, where he will oversee the company's Formulation Research and Development. Dr. Kadam holds a Ph.D and M. Pharm in Pharmaceutics, with over 20 years of experience in formulation and development of solid, liquid, and ophthalmic dosages for regulated markets including the US and EU. The disclosure is made under Regulation 30 of SEBI Listing Regulations.
This is a routine internal appointment and does not materially impact shareholders. The addition of an experienced R&D leader may support Caplin Point's formulation development pipeline, particularly for regulated markets, but is not expected to cause any immediate stock price movement.